ASCO 2026 Reveals LITESPARK-022 Trial’s Significant DFS Improvement with Adjuvant Pembrolizumab Plus Belzutifan in Renal Cell Carcinoma

August 9, 2026

Oncodaily USA

Overview

New insights into adjuvant therapy for renal cell carcinoma (RCC) were presented at the 2026 ASCO Annual Meeting. The LITESPARK-022 trial demonstrated that adjuvant pembrolizumab combined with belzutifan significantly improved disease-free survival (DFS) in patients. Concurrently, a ctDNA analysis from KEYNOTE-564, while showing prognostic potential, highlighted limitations for patient selection due to low baseline ctDNA positivity, despite pembrolizumab’s consistent DFS benefit.

In Depth

Key Findings

At the 2026 ASCO Annual Meeting, data from the LITESPARK-022 trial demonstrated that the combination of adjuvant pembrolizumab, an immune checkpoint inhibitor, and belzutifan, a hypoxia-inducible factor-2α (HIF-2α) inhibitor, significantly improved disease-free survival (DFS) in patients with renal cell carcinoma (RCC).

Technical / Clinical Details

The LITESPARK-022 trial evaluated the efficacy of this novel combination as an adjuvant therapy following nephrectomy for RCC. The results clearly indicated a superior DFS benefit for the combination therapy compared to monotherapy or placebo, establishing a potentially new benchmark for high-risk RCC patients. This represents a significant advancement in preventing disease recurrence. Concurrently, an analysis of circulating tumor DNA (ctDNA) from the KEYNOTE-564 trial was also presented at ASCO 2026. While this ctDNA analysis showed prognostic potential following adjuvant therapy, its utility for current patient selection is limited due to low baseline ctDNA positivity rates. Importantly, pembrolizumab demonstrated consistent DFS improvement irrespective of the patients’ baseline ctDNA status, reinforcing its broad applicability in the adjuvant setting for RCC.

Background & Context

Renal cell carcinoma remains a challenging malignancy, with a substantial proportion of patients experiencing recurrence even after successful surgical resection. Historically, effective adjuvant therapies to prevent recurrence have been a critical unmet need. While systemic therapies, including immunotherapies and targeted agents, have revolutionized the treatment of metastatic RCC, translating these successes into the adjuvant setting has proven difficult. The LITESPARK-022 trial’s findings offer a breakthrough, suggesting a synergistic effect between HIF-2α inhibition and immune checkpoint blockade that could fundamentally alter post-surgical management for high-risk RCC patients.

Strategic Significance & Outlook

The positive outcomes from the LITESPARK-022 trial are expected to accelerate the clinical adoption of the pembrolizumab plus belzutifan combination for adjuvant therapy in high-risk RCC. This promises improved recurrence-free survival and enhanced quality of life for a significant patient population. While ctDNA-based patient stratification currently faces limitations, ongoing research in this area is critical and holds immense potential for further personalizing RCC treatment in the future. These data collectively represent a pivotal moment in RCC treatment, offering new hope for patients and compelling opportunities for researchers, engineers, and investors in oncology therapeutics.

Source: https://oncodaily.com/genitourinary-oncology/renal-cell-carcinoma-2

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.